Salute e Benessere
CUTISS closes CHF 56M Series C round and signs agreement with leading EU burn center
The funds will also , a key component for bringing denovoSkin™ to market at scale.
CUTISS has also signed a , which could see the creation of CUTISS' first international commercial production facility in the Netherlands , once denovoSkin™ is approved. RKZ is a leading EU clinical trials center, participating in the Phase 2 and Phase 3 trials for denovoSkin™.
, stated: "The successful closing demonstrates confidence in our vision and ability to bring transformative skin therapies to patients. We're grateful for the continued trust of existing investors and warmly welcome new investors on board. Furthermore, the agreement with RKZ sets the stage for our future expansion with the potential to revolutionize the skin surgery market in Europe and globally."
, commented: "As a clinical institution dedicated to advancing burn care, we're committed to support CUTISS and the development of denovoSkin™. We're excited to continue our closer collaboration, and the agreement we've signed sets out our vision for bringing their revolutionary skin tissue therapy to our patients as a priority."
Further details regarding the announcement available here: https://cutiss.swiss/newsroom/
For media enquiries: Toomas Kull , kull@cpc-pr.com, +41 767 480 174
Photo - https://mma.prnewswire.com/media/2765893/CUTISS_denovoSkin.jpg
Logo - https://mma.prnewswire.com/media/2765892/CUTISS_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/cutiss-closes-chf-56m-series-c-round-and-signs-agreement-with-leading-eu-burn-center-302548028.html